Optimizing Heart Imaging for Women with Early-Stage Breast Cancer
This study is looking at ways to reduce the number of heart imaging tests (like echocardiograms) for women with early-stage breast cancer who are receiving HER2-targeted therapy. The goal is to see if a personalized approach can safely lower unnecessary tests while still catching any heart problems early. You may be able to join if you are a woman between 18 and 79 years old with HER2-positive breast cancer and a healthy heart function (LVEF ≥ 55%) before treatment. The study will measure how many imaging tests are done and how long it takes to complete your HER2 therapy. The current status of this study is unclear, and it plans to enroll 20 participants.
- Study design
- This interventional study plans to enroll 20 women. The phase of the study is not specified.
- What's involved
- You would undergo a 12-lead echocardiogram procedure. The study measures outcomes at the end of therapy, approximately 457 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures outcomes at the end of therapy, approximately 457 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Total Number of imaging testsAt the end of therapy, approximately 457 days
- Time to completion of HER 2 (human epidermal growth factor receptor 2) target therapy in daysend of therapy, approximately 457 days